Lungpacer announces participation and presentation at the LSI USA 2024 Conference

March 20, 2024

From LSI: “Lungpacer Medical (hashtag#LSIUSA24 Innovator) has designed the AeroPace® System to stimulate the nerves that activate the diaphragm muscle to rebuild diaphragm strength and shorten the time on mechanical ventilation for critical care patients.

Over a third of ventilated patients in ICUs require more than 4 days of mechanical ventilation. Studies have shown that the primary breathing muscle, the diaphragm, can atrophy over 50% in 2 to 3 days on mechanical ventilation due to inactivity.

This reduction in muscle strength can prolong the need for ventilation, decrease the chances of resuming independent breathing, and can lead to greater respiratory complications and mortality. With no available treatments, the FDA has recognized the Lungpacer AeroPace as a Breakthrough Device.

For patients unable to breathe on their own, AeroPace therapy provides repetitive exercise aiming to rebuild diaphragm muscle strength which is critical to healthy breathing. The AeroPace System is designed to integrate easily into current care pathways for acute care patients.

🌟 Lungpacer has recently achieved several major milestones including:

• A recent study published in the Journal of Anesthesiology showed that Lungpacer was associated with positive effects on lung mechanics and on hemodynamics in mechanically ventilated ARDS patients.
• Granted it 100th patent related to its technology portfolio
• Has extensive scientific evidence supporting its technology: 78 Scientific Abstracts and 5 Peer Reviewed Publications.
• Its pre-clinical and clinical studies have shown evidence that Lungpacer Therapy can reduce ventilator associated trauma to the diaphragm, lungs and brain and increase cardiac output.
• After two multi-national randomized clinical studies, Lungpacer Medical will be submitting a Premarket Approval to FDA for the AeroPace System in 2024.